7 Cremers F P, van den Hurk J A, den Hollander A I. Molecular genetics of Leber congenital amaurosis. Hum Mol Genet, 2002, 11: 1169-1176
[4]
11 Chung D C, Traboulsi E I. Leber congenital amaurosis: Clinical correlations with genotypes, gene therapy trials update, and future directions. J AAPOS, 2009, 13: 587-592
[5]
12 Maguire A M, High K A, Auricchio A, et al. Age-dependent effects of RPE65 gene therapy for Leber's congenital amaurosis: A phase 1 dose-escalation trial. Lancet, 2009, 374: 1597-1605
[6]
13 Simonelli F, Maguire A M, Testa F, et al. Gene therapy for Leber's congenital amaurosis is safe and effective through 1.5 years after vector administration. Mol Ther, 2009, 18: 643-650
[7]
15 Koenekoop R K, Wang H, Majewski J, et al. Mutations in NMNAT1 cause Leber congenital amaurosis and identify a new disease pathway for retinal degeneration. Nat Genet, 2012, 44: 1035-1039
[8]
1 Koenekoop R K. An overview of Leber congenital amaurosis: A model to understand human retinal development. Surv Ophthalmol, 2004, 49: 379-398
6 Chiang P W, Wang J, Chen Y, et al. Exome sequencing identifies NMNAT1 mutations as a cause of Leber congenital amaurosis. Nat Genet, 2012, 44: 972-974
[12]
8 den Hollander A I, Roepman R, Koenekoop R K, et al. Leber congenital amaurosis: Genes, proteins and disease mechanisms. Prog Retin Eye Res, 2008, 27: 391-419
[13]
9 Cideciyan A V. Leber congenital amaurosis due to RPE65 mutations and its treatment with gene therapy. Prog Retin Eye Res, 2010, 29: 398-427
14 Fainzilber M, Twiss J L. Tracking in the Wlds—the hunting of the SIRT and the luring of the Draper. Neuron, 2006, 50: 819-821
[16]
16 Perrault I, Hanein S, Zanlonghi X, et al. Mutations in NMNAT1 cause Leber congenital amaurosis with early-onset severe macular and optic atrophy. Nat Genet, 2012, 44: 975-977
[17]
17 Falk M J, Zhang Q, Nakamaru-Ogiso E, et al. NMNAT1 mutations cause Leber congenital amaurosis. Nat Genet, 2012, 44: 1040-1045
